Table 3: Comparison of epidemiological, clinical and treatment data in psoriatic arthritis patients with and without depression and correlation of depression with quality of life, age, disease duration and activity indexes.
COMPARISON STUDIES |
||||
|
With depression n = 28 (51.8%) |
Without depression n = 26 (48.1%) |
P |
|
Females/Males |
15/13 |
12/14 |
0.58 |
|
Tobacco exposure |
15 (53.3%) |
13 |
0.79 |
|
Polyarthritis |
10 (35.7%) |
4 (15.3%) |
0.42 |
|
Oligoarthritis |
14 (50%) |
16 (61.5%) |
||
Axial |
12 (42.8%) |
12 (46.1%) |
||
Distal interphalangeal |
2 (7.1%) |
3 (11.5%) |
||
Treatment |
||||
DMARDs (Methotrexate + leflunomide) |
18 (64.2%) |
16 (61.5%) |
0.83 |
|
Anti-TNF-alpha |
9 (32.1%) |
9 (34.6%) |
0.84 |
|
CORRELATION STUDIES OF CES-D QUESTIONNAIRE RESULTS |
||||
|
Rho |
95% Confidence interval |
P |
|
Age |
0.18 |
-0.09 to 0.43 |
0.18 |
|
Arthritis duration |
-0.008 |
-0.28 to +0.27 |
0.95 |
|
Psoriasis duration |
-0.004 |
-0.32 to +0.23 |
0.73 |
|
PASI |
0.50 |
+0.27 to +0.68 |
< 0.0001 |
|
ASDAS -ESR |
0.26 |
-0.01 to +0.50 |
0.057 |
|
ASDAS-CRP |
0.17 |
-0.10 to +0.43 |
0.20 |
|
CRP |
-0.04 |
-0.32 to +0.23 |
0.73 |
|
ESR |
0,14 |
-0.14 to 0.40 |
0.31 |
|
SF-12 (physical domain) |
-0.55 |
-0.71 TO -0.32 |
< 0.0001 |
|
SF-12 (mental domain) |
-0.80 |
-0.88 to -0.68 |
< 0.0001 |
DMARDs: Disease Modifying Rheumatic Drugs; PASI: Psoriasis Area Severity Index; ASDAS: Ankylosing Spondylitis Disease Score; ESR: Erythrocyte Sedimentation Rate; CRP: C Reactive Protein; SF-12: Short Form health survey with 12 questions; CES-D: Center for Epidemiologic Studies Depression scale